- Home
- ACM vs MDGL Comparison
ACM vs MDGL Comparison
Compare ACM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACM | MDGL |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 11.5B |
| IPO Year | 2007 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ACM | MDGL |
|---|---|---|
| Price | $71.44 | $525.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $131.30 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.3M | 257.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 42.71 | 41.32 |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $16,139,622,000.00 | $180,133,000.00 |
| Revenue This Year | N/A | $58.39 |
| Revenue Next Year | $6.06 | $48.55 |
| P/E Ratio | $36.41 | ★ N/A |
| Revenue Growth | ★ 0.21 | N/A |
| 52 Week Low | $67.64 | $265.00 |
| 52 Week High | $135.52 | $615.00 |
Technical Indicators
Market Signals| Indicator | ACM | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 26.22 | 53.44 |
| Support Level | N/A | $502.45 |
| Resistance Level | $86.74 | $556.79 |
| Average True Range (ATR) | 3.14 | 21.98 |
| MACD | -1.17 | -0.50 |
| Stochastic Oscillator | 20.68 | 51.98 |
Price Performance
Historical ComparisonAbout ACM AECOM
Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets including water, transportation, and environment. Based in Dallas, Aecom employs 51,000. The company generated $16.1 billion in sales in fiscal 2025.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.